From weeks to live to pioneering the Amyloidosis landscape
ARC's CEO, Isabelle Lousada, was told she had just weeks to live when she was diagnosed with AL Amyloidosis 25 years ago. A dedicated team of physicians at Boston Medical Center performed an experimental stem cell transplant, making Isabelle only...
Report From the Amyloidosis Forum Scientific Workshop
The Amyloidosis Forum, a Public Private Partnership with ARC and FDA, hosted the workshop on 22nd January, as part of an ongoing process to develop novel endpoints for clinical trial in AL amyloidosis. In 2020, the Amyloidosis Forum launched a...
First treatment for AL Amyloidosis approved in US
Daratumumab has just been granted approval by the FDA for the treatment of AL Amyloidosis in the United States. Today marks a major milestone and an achievement that has been years in the making. Janssen applied for FDA approval for...
Nobel Prize-Winning Science applied to ATTR Amyloidosis
A groundbreaking study in ATTR amyloidosis, using novel CRISPR/Cas9, has dosed the first patient in the UK. This revolutionary technology brings us a step closer to the dream of curing inherited diseases like hereditary amyloidosis. (more…)
Amyloidosis Forum launches series on novel endpoints and clinical trial design
The Amyloidosis Forum has launched a series of virtual meetings to focus on Novel Endpoints and Analyses for Clinical Trials in AL amyloidosis. The first meeting of the series took place on October 15th, 2020. (more…)